Login / Signup

Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.

Lori M B LaffelW V TamborlaneA YverG SimonsJ WuV NockD HobsonK S HughanS KaspersJ Marquard
Published in: Diabetic medicine : a journal of the British Diabetic Association (2018)
After a single oral dose of empagliflozin, adults and young people with Type 2 diabetes had similar exposure-response relationships after adjusting for significant covariates. These data support testing 10-mg and/or 25-mg doses of empagliflozin in an upcoming paediatric phase III Type 2 diabetes trial. (ClinicalTrials.gov registration no.: NCT02121483).
Keyphrases